首页 › 基金 › MPM BioImpact LLC › BLTE
MPM BioImpact LLC 对 BLTE 的持仓历史
BELITE BIO INC · 医疗保健
MPM BioImpact LLC 在 Q2 2026 的 13F 申报中披露持有 BLTE(BELITE BIO INC)137,208 股,市值约 US$21.1M,约占其申报组合的 1.29%,在其申报持仓中市值排名第 28 位。 MPM BioImpact LLC 最近 3 个申报季度中有 3 个季度披露了 BLTE 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
MPM BioImpact LLC 对 BLTE 的持仓演变
MPM BioImpact LLC 于 Q4 2025 首次披露 BLTE 持仓:87,760 股(约 US$14.0M)。 该持仓在 Q2 2026 达到峰值 137,208 股,市值约 US$21.1M。 在 3 次申报中,MPM BioImpact LLC 1 次增持、0 次减持、1 次保持不变。 最近一期申报(Q2 2026)显示持股 137,208 股、市值约 US$21.1M,环比增持 49,163 股。。 持仓曾出现大幅变动:Q2 2026 增持约 56% (随后一个季度股价上涨 10%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 87.76K | $14.04M | 新进 |
| Q1 2026 | 88.05K | $14.04M | 持有 |
| Q2 2026 | 137.21K | $21.13M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 BLTE 与 13F 数据
BLTE(BELITE BIO INC)属于医疗保健行业。我们追踪的基金中还有 68 只申报持有 BLTE,申报仓位最大的包括:Darwin Global Management, Ltd. (US$456.6M), Paradigm Biocapital Advisors LP (US$189.8M), RTW INVESTMENTS, LP (US$110.2M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 BLTE 的基金
- Darwin Global Management, Ltd. 3.08M 股 · $456.59M · Q2 2026
- Paradigm Biocapital Advisors LP 1.23M 股 · $189.84M · Q2 2026
- RTW INVESTMENTS, LP 715.33K 股 · $110.15M · Q2 2026
- Maverick 资本 396.31K 股 · $61.03M · Q2 2026
- MAVERICK CAPITAL LTD 396.31K 股 · $61.03M · Q2 2026
- EVENTIDE ASSET MANAGEMENT, LLC 390.83K 股 · $60.18M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 357.20K 股 · $55.00M · Q2 2026
- Logos Global Management LP 250.00K 股 · $38.50M · Q2 2026
- Affinity Asset Advisors, LLC 165.00K 股 · $25.41M · Q2 2026
- Patient Square Capital LP 110.00K 股 · $16.94M · Q2 2026
- Artia Global Partners LP 24.99K 股 · $3.85M · Q2 2026
- BALANCE CAPITAL PARTNERS L.P. 22.50K 股 · $3.46M · Q2 2026
更多关于 MPM BioImpact LLC
常见问题
How long has MPM BioImpact LLC held BLTE?
MPM BioImpact LLC has disclosed BLTE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is MPM BioImpact LLC's current position in BLTE?
As of Q2 2026, MPM BioImpact LLC holds 137.21K shares of BLTE (BELITE BIO INC), valued at $21.13M, representing 1.29% of its reported portfolio and ranking #28.
Has MPM BioImpact LLC been buying or selling BLTE?
In the latest 13F filing (Q2 2026), MPM BioImpact LLC increased its position in BLTE. The position peaked in Q2 2026 at 137.21K shares.
Which other funds hold BLTE?
Other major institutional holders of BLTE include Darwin Global Management, Ltd., Paradigm Biocapital Advisors LP, RTW INVESTMENTS, LP, among 68 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.